April 27, 2018

Huntsman Cancer Institute, South Auditorium. View driving directions.

This conference is provided free of charge to attendees, but registration is required. Register Now


This one-day conference brings together basic researchers and clinicians with an interest in immunotherapies as promising approaches
for patients with different types of cancer. The conference will provide an update on the most recent developments in the field of cancer immunotherapy and it will facilitate collaborative efforts between basic tumor immunologists and oncologists/hematologists using novel immunotherapeutic approaches to the benefit of their patients. This conference will help us to identify the most promising immunotherapies for our patients leading to improved outcomes and maybe even cures.

Target Audience

This conference is for anyone treating patients with cancer such as medical oncologists, hematologists, surgical oncologists, radiation oncologists, primary
 care physicians, pharmacists, physician assistants, advanced practice nurses, and nurses. It is also for basic researchers interested in the role of the immune environment in cancer development and progression, the relevance of cancer immunosurveillance, tumor-specific immune responses, and the design of novel cancer immunotherapies.

Educational Objective

Accme Accredited

Accreditation: The University Of Utah School Of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

AMA Credit: The University of Utah School of Medicine designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NONDISCRIMINATION AND DISABILITY ACCOMMODATION STATEMENT: The University of Utah does not exclude, deny benefits to or otherwise discriminate against any person on the basis of race, color, national origin, ethnicity, sex, disability, age, veteran’s status, religion, gender identity, gender expression, genetic information, or sexual orientation in admission to or participation in its programs and activities.  Reasonable accommodations will be provided to qualified individuals with disabilities upon request, with reasonable notice.  Requests for accommodations or inquiries or complaints about University nondiscrimination and disability/access policies may be directed to the Director, OEO/AA, Title IX/Section 504/ADA Coordinator, 201 S President’s Circle, RM 135, Salt Lake City, UT 84112, 801-581-8365 (Voice/TTY), 801-585-5746 (Fax).

Conference Chairs


Djordje Atanackovic, MD
Director, Multiple Myeloma Program & Cancer Immunotherapy
Huntsman Cancer Institute / University of Utah


Tim Luetkens, MD
Ryan O’Connell, PhD

Please contact Callee LaPlant at callee.laplant@hci.utah.edu or 801-585-3599 if you have questions or need additional information.